(Q36299405)

13 August 2017

1 reference

title

Modulating processes within the central nervous system is central to therapeutic control of multiple sclerosis (English)

1 reference

13 August 2017

0 references

1

Tjalf Ziemssen

1 reference

13 August 2017

publication date

1 November 2005

1 reference

13 August 2017

1 reference

13 August 2017

volume

252 Suppl 5

1 reference

13 August 2017

page(s)

v38-45

1 reference

Cellular sources of enhanced brain-derived neurotrophic factor production in a mouse model of allergic inflammation

13 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00415-005-5007-2

Insulin-like growth factor-1 fails to enhance central nervous system myelin repair during autoimmune demyelination

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00415-005-5007-2

Mechanisms of action of glatiramer acetate in multiple sclerosis

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00415-005-5007-2

Tumor necrosis factor blockade in actively induced experimental autoimmune encephalomyelitis prevents clinical disease despite activated T cell infiltration to the central nervous system

21 January 2018

1 reference

12 December 2020

Cutting edge: clonally restricted production of the neurotrophins brain-derived neurotrophic factor and neurotrophin-3 mRNA by human immune cells and Th1/Th2-polarized expression of their receptors.

1 reference

12 December 2020

BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells?

1 reference

12 December 2020

The neuregulin, glial growth factor 2, diminishes autoimmune demyelination and enhances remyelination in a chronic relapsing model for multiple sclerosis

1 reference

12 December 2020

Human nerve growth factor protects common marmosets against autoimmune encephalomyelitis by switching the balance of T helper cell type 1 and 2 cytokines within the central nervous system

1 reference

12 December 2020

Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor

1 reference

12 December 2020

Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration

1 reference

12 December 2020

LIF receptor signaling limits immune-mediated demyelination by enhancing oligodendrocyte survival

1 reference

12 December 2020

Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation?

1 reference

12 December 2020

Neuroprotection and glatiramer acetate: the possible role in the treatment of multiple sclerosis.

1 reference

12 December 2020

Cellular pathology of Parkinson's disease: astrocytes, microglia and inflammation

1 reference

12 December 2020

Adenoviral gene transfer of ciliary neurotrophic factor and brain-derived neurotrophic factor leads to long-term survival of axotomized motor neurons

1 reference

12 December 2020

Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions

1 reference

12 December 2020

Protective autoimmunity and neuroprotection in inflammatory and noninflammatory neurodegenerative diseases

1 reference

12 December 2020

1 reference

12 December 2020

Axonal damage in multiple sclerosis: a complex issue in a complex disease

1 reference

12 December 2020

Unimpaired autoreactive T-cell traffic within the central nervous system during tumor necrosis factor receptor-mediated inhibition of experimental autoimmune encephalomyelitis

1 reference

12 December 2020

Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis.

1 reference

12 December 2020

Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis.

1 reference

12 December 2020

Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials

1 reference

12 December 2020

Immune-mediated neurodegeneration and neuroprotection in MS.

1 reference

12 December 2020

TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group

1 reference

12 December 2020

Therapeutic strategies to prevent neurodegeneration and promote regeneration in multiple sclerosis.

1 reference

12 December 2020

Glatiramer acetate-reactive T cells produce brain-derived neurotrophic factor

1 reference

12 December 2020

Insulin-like growth factor-I treatment reduces immune cell responses in acute non-demyelinative experimental autoimmune encephalomyelitis

1 reference

12 December 2020

The role of the humoral immune system in multiple sclerosis (MS) and its animal model experimental autoimmune encephalomyelitis (EAE).

1 reference

12 December 2020

Inhibition of autoimmune encephalomyelitis by a tetracycline.

1 reference

12 December 2020

Role of nerve growth factor in experimental autoimmune encephalomyelitis

1 reference

12 December 2020

Multiple sclerosis: a two-stage disease

1 reference

12 December 2020

Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation

1 reference

12 December 2020

Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia.

1 reference

12 December 2020

Multiple paradigm shifts in multiple sclerosis

1 reference

12 December 2020

1 reference

12 December 2020

Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis

1 reference

12 December 2020

Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy

1 reference

12 December 2020

Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis

1 reference

12 December 2020

Anti-inflammatory activity of nerve growth factor in experimental autoimmune encephalomyelitis: inhibition of monocyte transendothelial migration.

1 reference

12 December 2020

Neurotrophic cross-talk between the nervous and immune systems: implications for neurological diseases

1 reference

12 December 2020

Regulation of experimental autoimmune encephalomyelitis with insulin-like growth factor (IGF-1) and IGF-1/IGF-binding protein-3 complex (IGF-1/IGFBP3).

1 reference

12 December 2020

10.1007/S00415-005-5007-2

Identifiers

DOI

1 reference

13 August 2017

1 reference